D
Dan-Arin Silasi
Researcher at Yale University
Publications - 130
Citations - 5224
Dan-Arin Silasi is an academic researcher from Yale University. The author has contributed to research in topics: Cancer & Ovarian cancer. The author has an hindex of 34, co-authored 127 publications receiving 4247 citations. Previous affiliations of Dan-Arin Silasi include Bridgeport Hospital.
Papers
More filters
Journal ArticleDOI
Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance.
Ayesha B. Alvero,Rui Chen,Han-Hsuan Fu,Michele K. Montagna,Peter E. Schwartz,Thomas J. Rutherford,Dan-Arin Silasi,Karina Dahl Steffensen,Marianne Waldstrøm,Irene Visintin,Gil Mor +10 more
TL;DR: The identification and cloning of human OCSCs can aid in the development of better therapeutic approaches for ovarian cancer patients and explain some of the unique characteristics of CSCs that control self-renewal and drive metastasis.
Journal ArticleDOI
TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer.
Michael G. Kelly,Ayesha B. Alvero,Rui Chen,Dan-Arin Silasi,Vikki M. Abrahams,Serena Chan,Irene Visintin,Thomas J. Rutherford,Gil Mor +8 more
TL;DR: It is proposed that the TLR-4-MyD88 signaling pathway may be a risk factor for developing cancer and may represent a novel target for the development of biomodulators.
Journal ArticleDOI
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
Amanda N. Fader,Dana M. Roque,Eric R. Siegel,Natalia Buza,Pei Hui,Osama Abdelghany,Setsuko K. Chambers,Angeles Alvarez Secord,Laura J. Havrilesky,David M. O'Malley,Floor J. Backes,Nicole S. Nevadunsky,Babak Edraki,Dirk Pikaart,William J. Lowery,K. ElSahwi,Paul Celano,Stefania Bellone,Masoud Azodi,Babak Litkouhi,Elena Ratner,Dan-Arin Silasi,Peter E. Schwartz,Alessandro D. Santin +23 more
TL;DR: Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival, and no unexpected safety signals emerged.
Journal ArticleDOI
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.
Siming Zhao,Murim Choi,John D. Overton,Stefania Bellone,Dana M. Roque,Emiliano Cocco,Federica Guzzo,Diana P. English,Joyce Varughese,Sara Gasparrini,Ileana Bortolomai,Natalia Buza,Pei Hui,Maysa M. Abu-Khalaf,Antonella Ravaggi,Eliana Bignotti,Elisabetta Bandiera,Chiara Romani,Paola Todeschini,Renata A. Tassi,Laura Zanotti,Luisa Carrara,Sergio Pecorelli,Dan-Arin Silasi,Elena Ratner,Masoud Azodi,Peter E. Schwartz,Thomas J. Rutherford,Amy L. Stiegler,Shrikant Mane,Titus J. Boggon,Joseph Schlessinger,Richard P. Lifton,Alessandro D. Santin +33 more
TL;DR: Analysis of whole-exome sequencing of 57 cancers identified frequent mutation of DNA damage, chromatin remodeling, cell cycle, and cell proliferation pathways in USC and suggest potential targets for treatment of this lethal variant of endometrial cancer.
Journal ArticleDOI
Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells.
TL;DR: The TLRs serve as cell surface sensors that can initiate pathways leading to proliferation and chemoresistance; as well as mediators that are able to regulate the infiltrating immune cells to provide further support for cancer progression.